Open | - |
Close | - |
Volume / Avg. | 0 / 648.018K |
Day Range | - - - |
52 Wk Range | 13.820 - 24.210 |
Market Cap | $1.944B |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 47 |
Short Interest | 5.69% |
Days to Cover | 6.39 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Myriad Genetics (NASDAQ: MYGN) through any online brokerage.
Other companies in Myriad Genetics’s space includes: Twist Bioscience (NASDAQ:TWST), Avidity Biosciences (NASDAQ:RNA), Syndax Pharmaceuticals (NASDAQ:SNDX), TG Therapeutics (NASDAQ:TGTX) and PTC Therapeutics (NASDAQ:PTCT).
The latest price target for Myriad Genetics (NASDAQ: MYGN) was reported by Goldman Sachs on Tuesday, January 30, 2024. The analyst firm set a price target for 31.00 expecting MYGN to rise to within 12 months (a possible 43.32% upside). 14 analyst firms have reported ratings in the last year.
The stock price for Myriad Genetics (NASDAQ: MYGN) is $21.63 last updated March 18, 2024 at 4:00 PM EDT.
There are no upcoming dividends for Myriad Genetics.
Myriad Genetics’s Q1 earnings are confirmed for Wednesday, May 1, 2024.
There is no upcoming split for Myriad Genetics.
Myriad Genetics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.